Nutrition and cardiovascular aging · Research Analysis
PREDIMED found fewer cardiovascular events after a Mediterranean-style diet—with a correction history
In 7,447 high-risk adults, both supplemented Mediterranean-diet groups had fewer composite cardiovascular events than control. The original report was withdrawn and replaced after allocation deviations were identified.
Source, correction-status, evidence, safety and prose reviews were completed July 31, 2026.
Evidence box
Promising cardiovascular outcome evidence; not a human longevity trial
- Study type
- Multicenter randomized dietary trial with corrected analyses
- Studied in
- Adults aged 55–80 in Spain at high cardiovascular risk, without cardiovascular disease at enrollment
- Participants / sample
- 7,447 participants; 288 primary composite events over median 4.8 years
- Publication status
- 2013 report retracted; corrected and republished in 2018
- Outcome type
- Myocardial infarction, stroke or cardiovascular death composite
- Development stage
- Available dietary pattern; disease-prevention research
- Conflicts / funding
- Spanish public funding and others; intervention foods supplied free; paper disclosures checked
- Our assessment
- Promising for the scoped cardiovascular composite; not evidence of slower aging or longer life
- Reporting confidence
- High for corrected event counts; moderated by known allocation deviations
The bottom line
The corrected PREDIMED report found fewer major cardiovascular events among high-risk adults assigned a Mediterranean-style program supplemented with extra-virgin olive oil or nuts than among those assigned advice to reduce dietary fat. The absolute event proportions were 3.8%, 3.4% and 4.4%, respectively. The study did not test biological aging or lifespan, and its correction history is essential to interpreting the result. (corrected report; retraction/republication notice)
Why this matters
PREDIMED is frequently cited far beyond cardiovascular prevention. A clinically meaningful disease endpoint is more informative than a biomarker, but it still answers a defined question in a defined population. Calling the result “anti-aging” would erase the trial’s comparator, foods, risk profile, endpoint and methodological history.
What researchers did
Investigators enrolled 7,447 adults aged 55–80 at high cardiovascular risk but without cardiovascular disease at baseline. Participants were assigned to a Mediterranean diet plus extra-virgin olive oil, the diet plus mixed nuts, or advice to reduce dietary fat. Intervention groups received quarterly education and free supplemental foods. Median follow-up was 4.8 years; the primary endpoint combined myocardial infarction, stroke and cardiovascular death.
What they found
There were 96 events among 2,543 participants in the olive-oil group (3.8%), 83 among 2,454 in the nuts group (3.4%), and 109 among 2,450 controls (4.4%). Adjusted hazard ratios versus control were 0.69 (95% CI 0.53–0.91) and 0.72 (0.54–0.95). Five-year absolute risks were estimated as 3.6%, 4.0% and 5.7%. All-cause mortality estimates were not conclusive. These are cardiovascular results, not measures of aging rate.
How strong is the evidence?
The large sample, adjudicated clinical endpoint and consistency across revised sensitivity analyses are strengths. But the investigators found household enrollment without individual randomization, nonrandom assignment at one of 11 sites and apparently inconsistent randomization-table use at another. The 2018 analyses adjusted for baseline characteristics and propensity scores and remained similar after excluding 1,588 suspect assignments. That repair improves interpretability; it cannot make the deviations disappear.
What this study does not show
The trial cannot identify which food or behavior caused the difference, show benefit in every population, or establish that the program slows biological aging. A reduction in a cardiovascular composite does not prove longer life; all-cause mortality did not show a clear difference. The interventions also included counseling and free olive oil or nuts, so the result is not evidence for any product carrying a “Mediterranean” label.
Safety and conflicts
No relevant diet-related adverse effects were reported in the corrected paper, but dietary suitability varies with allergy, disease, medication and nutritional needs. The trial received Spanish public funding and other support, and intervention foods were provided. The complete paper disclosures should be read alongside the result. This article does not prescribe a meal plan.
What happens next
Replication with fully documented allocation, comparable intervention support and prespecified clinical outcomes would clarify certainty and generalizability. A 2025 synthesis found low or very low certainty for most cardiovascular risk-factor outcomes and some concerns or high risk of bias in 85% of included trials—an important reminder that the wider literature is not one uniformly strong block.
Primary sources
Sources, roles and limits
- Estruch et al., corrected and republished PREDIMED report
- Identifier
- PMID:29897866 · DOI:10.1056/NEJMoa1800389 · ISRCTN35739639
- Role
- Primary corrected trial report
- Limitation
- Known allocation deviations; high-risk Spanish population; cardiovascular composite, not aging.
- Retraction and republication notice
- Identifier
- PMID:29897867 · DOI:10.1056/NEJMc1806491
- Role
- Correction and publication-history record
- Limitation
- Explains why the 2013 report cannot be cited as the current result.
- Hernandez et al., randomized-trial systematic review
- Identifier
- PMID:39783962 · DOI:10.1080/27697061.2024.2440051
- Role
- Current synthesis and risk-of-bias context
- Limitation
- Clinical outcome evidence was sparse and largely came from corrected PREDIMED.
- PREDIMED trial registry
- Identifier
- ISRCTN35739639
- Role
- Trial identity
- Limitation
- Registration is not government endorsement or independent proof of benefit.
Connected topics
Continue through the knowledge system
Disclosures and history
- July 31, 2026 — discovery, counterevidence and claim-level integration passes completed before prose drafting.
- July 31, 2026 — identifiers, correction status, conflicts, evidence scope and safety context verified; standing publication authorization applied.